

Formulation Development and Evaluation of Tablet Formulation Containing Ibuprofen HCL with Castor Oil

Gayatri Burte^{1*}, Vikram Veer², Ashok Bhosale³

¹Second Year M Pharmacy, ²Professor, ³Principal,

^{1,2,3}PDEA Shankarrao Ursal College of Pharmaceutical Science and Research Centre, Kharadi, Pune, Maharashtra, India

ABSTRACT

The purpose of this study was to formulate and evaluate conventional tablets of Ibuprofen HCL with Castor oil. Castor oil helps to overcome the hepatotoxic effect of Ibuprofen HCL. Direct compression method was used to formulate tablets, which contained Castor oil in different proportion from batch F1-F4. Formulation of tablets was prepared by the powder blend of different ratios of Castor oil to get desirable drug release profile. All batches were evaluated for flow property (Pre compression study). Evaluation parameters of formulated tablets were hardness, friability, thickness, drug content, weight variation, and the in-vitro drug release rate pattern. Results indicated that the formulation F2 was the most promising formulation as the drug release from this formulation was high as compared to other formulations. In formulation F2, percentage drug release of Ibuprofen HCL is 97.01% at 60 min.

KEYWORDS: *Ibuprofen HCL, Castor oil, Conventional tablet, NSAIDs, Direct Compression*

INTRODUCTION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class FDA-approved for use as antipyretic, anti-inflammatory, and analgesic agents. These effects make NSAIDs useful for treating muscle pain, dysmenorrhea, arthritic conditions, pyrexia, gout, migraines, and used as opioid-sparing agents in certain acute trauma cases. NSAIDs are typically divided into groups based on their chemical structure and selectivity: acetylated salicylates (aspirin), non-acetylated salicylates (diflunisal, salsalate), propionic acids (naproxen, ibuprofen, acetic acids (diclofenac, indomethacin), enolic acids (meloxicam, piroxicam) anthranilic acids (meclofenamate, mefenamic acid), naphthylalanine (nabumetone), and selective COX-2 inhibitors (celecoxib, etoricoxib). Topical NSAIDs (diclofenac gel) are also available for use in acute tenosynovitis, ankle sprains, and soft tissue injuries. It is common to use NSAIDs to ease minor and short-term inflammation and pain. Some conditions that may cause temporary pain include: arthritis,

backache, cold or flu, headaches, period pain., joint or bone injuries, sprains, and strains, muscle or joint complaints, toothache If any of these problems become chronic, a person should consider the safety of using NSAIDs. NSAIDs work by preventing an enzyme (a protein that triggers changes in the body) from doing its job. The enzyme is called cyclooxygenase, or COX, and it has two forms. COX-1 protects the stomach lining from harsh acids and digestive chemicals. It also helps maintain kidney function. COX-2 is produced when joints are injured or inflamed. NSAID toxicity can manifest as GI bleeding, hypertension, hepatotoxicity, and renal damage. Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, menstrual cramps, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. For ongoing conditions such as arthritis, Castor oil have hepatoprotective, choleric and anticholestatic

How to cite this paper: Gayatri Burte | Vikram Veer | Ashok Bhosale "Formulation Development and Evaluation of Tablet Formulation Containing Ibuprofen HCL with Castor Oil" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-4, June 2022, pp.1786-1794, www.ijtsrd.com/papers/ijtsrd50389.pdf



IJTSRD50389

URL:

www.ijtsrd.com/papers/ijtsrd50389.pdf

Copyright © 2022 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (<http://creativecommons.org/licenses/by/4.0>)



activity. Castor oil is a promising commodity that has a variety of applications in the coming years, particularly as a renewable energy source. It is used as a powerful laxative, A natural moisturizer, may promote wound healing, May be helpful for cleaning and storing dentures. Castor oil has no noted interactions with other drugs. Direct compression is employed to define the method by which tablets are compressed directly from powder blend of active ingredients and suitable excipients, which will flow uniformly within the die cavity and forms a firm compact.

Materials and Methods:

Ibuprofen HCl was provided by Solanki pharmaceuticals, (Pune, India). Fine Chem Ltd. (Mumbai, India) supplied Castor oil, Stearic acid, Sodium bicarbonate, Silicon dioxide, Lactose. All of the reagents used in this experiment was analytical quality grade.

Methods:

Method for Preparation of Tablets:

Dry granulation:

This method is used for tablet preparation, in case tablet ingredients are highly sensitive to moisture, or unable to with stand elevated temperatures during drying, slugging may be used to form the granules. Dry granulation or double compression, usually eliminates various steps, which involves slugging of the powder mass. The active ingredient, diluent and

lubricant are blended together, to form the slug. Thus, the compressed slug is passed through the mesh or through the mill, and the remaining lubricant is added to the granulation, blended properly and compressed to form the tablets.

Direct Compression:

In which tablets formulations are directly compressed from a powder blend of suitable excipients and API is called a direct compression method. Pre-treatment of blended powder by dry necessary In this formulation. It provides merits mostly in terms of speedy production, as it requires less machinery, reduced number of personnel, fewer unit operations and significantly less processing time along with improved product stability. So, In this formulation direct compression method was used.

Identification of pure drug:

Identification of pure drug was carried out by UV-Visible spectroscopy and Fourier Transform Infra-Red Spectrophotometry scanned in the range of 200-400nm. Also Identification of pure drug was carried out by Differential Scanning Calorimetry (DSC) study.

Drug-excipient compatibility study:

Studies of drug-excipient compatibility are important to ascertain drug and excipients are compatible with each other. Differential Scanning Calorimetry (DSC) study and are used to study drug-excipient compatibility.

UV-Spectroscopy:

The stock solution of Ibuprofen HCl was prepared in Methanol; UV spectrum of 10 μ g/ml solution of Ibuprofen HCl was taken to determine its absorption maxima (λ max). The dissolved Ibuprofen Hydrochloride showed an absorbance maximum (λ max) at 224 nm. The linearity of the responses of both drugs was verified at 2–12 μ g/ml concentrations. The calibration curve was obtained by plotting the absorbance versus the concentration data and was treated by linear regression analysis. The equation of the linearity curve for Ibuprofen HCl obtained was $y = 0.0806x + 0.0089$. The linearity curve was found to be linear for mentioned concentrations (the correlation coefficient (r^2) of determination was 0.9996 (Fig.1).




Fig.1 UV Calibration Curve of Ibuprofen Hydrochloride

FTIR spectroscopy:

FTIR (Shimadzu 8400s) spectrophotometer were used in the range of 400-4000 cm^{-1} using potassium bromide discs (Mixing ratio 1:1) The samples were hermetically sealed in aluminum pans and heated at a constant rate of $10^\circ\text{C}/\text{min}$ over a temperature range of 40 to 300°C . The FTIR spectrums of pure drug Ibuprofen HCl were studied. It was observed that there were no major shifts in the main peaks of drug Ibuprofen HCl. This indicates that drug is in pure form. Ibuprofen HCl had peaks at 3325.29 (O-H stretching), 2870.17 (C-H3 stretching), and 1712.85 (C=O stretching), 1512.24 (C=C stretching) (**Fig.2**).




Fig.2 IR Spectrum of Ibuprofen Hydrochloride

Differential Scanning Calorimetry (DSC) study:

Mettler Toledo (*SW920) Differential Scanning Calorimeter using aluminum pans equipped with an intracooler and a refrigerated cooling system was used to analyse the thermal behavior of Ibuprofen HCl, Indian standard was used to calibrate the DSC temperature. The thermal behavior of hermetically sealed samples heated at $10^\circ\text{C}/\text{min}$.

DSC Thermogram of Ibuprofen HCl is shown in **Fig.3** Thermogram indicates a sharp endotherm at 78.97°C , which is corresponding to the melting point of Ibuprofen HCl. From this it is concluded that the given sample of Ibuprofen HCl is in pure form.

Compatibility studies were performed in order to confirm the drug-excipient compatibility. The physical mixtures of Ibuprofen HCl + Castor oil and other excipients, were taken as 1:1 ratio. DSC Thermogram of given sample of Ibuprofen HCl + Castor Oil and other excipients is shown in **Fig.4**. Thermogram indicates a sharp endotherm at 80°C , which is corresponding to the melting point of Ibuprofen HCl. From this it is concluded that the given sample of Ibuprofen HCl + Castor oil and other excipients is compatible with each other.




Fig.3 DSC Thermogram of Ibuprofen hydrochloride




Fig.4 DSC Thermogram of Physical Mixture of Ibuprofen Excipient

Formulation of tablet:

Formulation of tablet blend for Tablets of Ibuprofen HCl. The tablet blends for different batch formulation(F1-F4) are prepared and further studied for Pre-compression properties and subjected for tablet punching by direct compression.

Table.1 Formulation of Tablet Batches (500 mg).

| Sr. No. | Ingredients | Batch | Batch | Batch | Batch |
|---------|--------------------|--------|--------|--------|--------|
| | | F1(mg) | F2(mg) | F3(mg) | F4(mg) |
| 01 | Ibuprofen HCl | 400 | 400 | 400 | 400 |
| 02 | Castor oil | 20 | 40 | 60 | 80 |
| 03 | Stearic acid | 06 | 06 | 06 | 06 |
| 04 | Sodium bicarbonate | 02 | 02 | 02 | 02 |
| 05 | Lactose | 68 | 48 | 28 | 08 |
| 06 | Silicon dioxide | 04 | 04 | 04 | 04 |

Results:

Precompression study:

Evaluation of prepared tablet blends for pre compression study:

The mass-volume relationship characteristics of a mixed blend were determined by characterization. Angle of repose, bulk density, and tapped density were all examined, with Hausser's ratio and compressibility index given in **Table.2**

Table.2 Flow Properties of Ibuprofen Hydrochloride Blend

| Test | F1 | F2 | F3 | F4 |
|-----------------------|----------------|----------------|---------------|---------------|
| Bulk Density | 0.4761 ± 0.002 | 0.4821 ± 0.006 | 0.450 ± 0.003 | 0.465 ± 0.002 |
| Tapped Density | 0.5333 ± 0.006 | 0.5284 ± 0.002 | 0.502 ± 0.008 | 0.523 ± 0.003 |
| Compressibility Index | 10.725 ± 0.40 | 8.8460 ± 0.30 | 10.35 ± 0.44 | 11.08 ± 0.20 |
| Hausner's Ratio | 1.120 ± 0.02 | 1.096 ± 0.03 | 1.11 ± 0.04 | 1.12 ± 0.03 |
| Angle of repose | 19.87 ± 0.4 | 19.02 ± 0.2 | 17.98 ± 0.4 | 19.65 ± 0.1 |

Results are mean of three determinations

Evaluation of Tablets:

The prepared tablets subjected for weight variation, thickness, hardness, friability, drug content, In-vitro disintegrating time, In-vitro dissolution studies, Assay were carried out.



Fig.5 Formulated Ibuprofen Tablets

Table 3 Evaluations of Tablets

| Batch | % Weight Variation (% w/w) | Hardness (Kg/cm ²) | Thickness (mm) | % Friability | Disintegration Time |
|-------|----------------------------|--------------------------------|----------------|--------------|---------------------|
| F1 | 499.39 ±1.12 | 4.0 ± 0.3 | 5.1 ± 0.02 | 0.68 ±0.035 | 5 Min. 23 Sec. |
| F2 | 500.12 ±1.18 | 4.2 ± 0.1 | 5.2 ± 0.03 | 0.63 ±0.046 | 8 Min. 44 Sec. |
| F3 | 498.24 ±1.14 | 4.1 ± 0.4 | 4.9 ± 0.08 | 0.59 ±0.048 | 6 Min. 21 Sec. |
| F4 | 501.32 ±1.47 | 4.0 ± 0.5 | 5.0 ± 0.09 | 0.64 ±0.023 | 7 Min. 20 Sec. |

Results are mean of three determinations

Dissolution Study

Dissolution of Formulation Batch F1-F4 for Ibuprofen hydrochloride by using dissolution test apparatus and UV Spectrophotometer.

Apparatus: - Apparatus No.2, Medium: - 900 ml of Phosphate buffer PH (7.2).

Speed and time: - 100 rpm and 60 minutes

Procedure: -

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0µm, rejecting the first few ml of the filtrate.

Dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance at 224 nm of the solution of known concentration of Ibuprofen. Calculate the content of Ibuprofen HCl. limit is Not less than 75% of the stated amount of ibuprofen

Table.4 Dissolution study of Ibuprofen HCl Tablet

| Time (Min) | F1 (%) | F2 (%) | F3 (%) | F4 (%) |
|------------|---------------|----------------------|---------------|---------------|
| 0 | 0 | 0 | 0 | 0 |
| 5 | 5.798 ± 0.78 | 6.581 ± 0.55 | 6.189 ± 0.17 | 5.509 ± 0.51 |
| 10 | 13.099 ± 0.21 | 15.200 ± 0.43 | 14.244 ± 0.47 | 12.100 ± 0.11 |
| 15 | 25.862 ± 0.44 | 41.072 ± 0.24 | 33.742 ± 0.36 | 32.047 ± 0.52 |
| 30 | 60.121 ± 0.74 | 64.047 ± 0.65 | 54.312 ± 0.28 | 54.616 ± 0.63 |
| 45 | 79.924 ± 0.62 | 85.139 ± 0.98 | 84.443 ± 0.33 | 83.125 ± 0.47 |
| 60 | 88.717 ± 0.48 | 97.017 ± 0.62 | 94.265 ± 0.64 | 95.583 ± 0.12 |

Results are mean of three determinations




Fig.5 Cumulative In-vitro Dissolution Study

The formulation **F2** selected as a optimized formulation because of this batch showed satisfactory result of the tablets evaluation parameters. Result of in vitro % drug release profile indicated that formulation (F2) was the most promising formulations as the drug release from this formulation and assay was high as compared to other formulations. So, **F2** was found to be optimized formulation and was selected for further Assay and stability study.

Assay:

% Assay of Selected Formulation Batch F2 for Ibuprofen HCl is **101.77 %**

Stability study:

Stability study for the developed formulation F2 were carried out as per ICH guideline by storing at 40°C/75% RH up to one month. The formulation F27 was selected on the basis of their high cumulative percentage drug release. shows Cumulative percent release of F2 Formulation after three months which shows stability of formulation.

Table.5 Stability Study of Optimized Formulation F2 batch

| Sr. No. | Parameter | Initial | After three months |
|---------|---------------------|--------------|--------------------|
| 01 | Hardness | 4.2 | 4.2 |
| 02 | Thickness | 5.2 | 5.2 |
| 03 | Friability | 0.19 % | 0.23% |
| 04 | Weight Variation | 500.12±0.10% | 500.12 ±0.11% |
| 05 | Disintegration Time | 8 Min 44Sec. | 8 Min 59 Sec. |
| 06 | % Drug Release | 98.79±0.09% | 98.33±0.09 % |
| 07 | % Assay | 101.77±0.12 | 101.20±0.1 |

Results are mean of three determinations

The stability study showed that the formulation F2 was physically stable when stored at 40±20°C and 75±5% RH for three months and there was no significant difference in dissolution parameters of optimized formulation.

Conclusion:

The present study was undertaken with an aim to formulate, develop and evaluate tablet of Ibuprofen with Castor oil. Preformulation study was done initially and result directed for the further course of formulation. Based on preformulation studies different batches of Ibuprofen hydrochloride was prepared using selected excipients. Powders were evaluated for tests angle of repose, bulk density, tapped density, compressibility index, and Hausner's ratio before being compressed as tablets. Various formulation of tablets of Ibuprofen hydrochloride and castor oil were developed using various concentrations of binders by dry granulation technique. The tablets were evaluated for physical observations, in vitro release study and stability studies. Observations of all formulation for physical observation had shown that, all of them comply with the specifications of official pharmacopoeias and/or standard references. Result of in vitro release profile indicated that formulation (**F2**) was the most promising formulations as the drug release from this formulation was high as compared to other formulations. The cumulative % of drug release of formulation F2 was 98.79% respectively, and % of drug assay of formulation F2 for Ibuprofen with castor oil was found 101.77±0.12%.

Acknowledgement:

For the completion of the research work the authors would like to show sincere gratitude to PDEA'S Shankarrao Ursal College of Pharmaceutical Sciences & Research Centre, Kharadi, Pune to provide with a lot of support and help whenever needed

References:

- [1] <https://orthoinfo.aaos.org/en/treatment/what-are-nsaids/>
- [2] <https://www.ncbi.nlm.nih.gov/books/NBK547742/>.
- [3] <https://www.medicalnewstoday.com/articles/179211>
- [4] <https://www.webmd.com/drugs/2/drug-5166-9368/ibuprofen-oral/ibuprofen-oral/details>
- [5] <https://www.healthline.com/nutrition/castor-oil>
- [6] https://www.rxlist.com/consumer_castor_oil/drugs-condition.htm
- [7] Visen PK, Shukla B, Patnaik GK, Tripathi SC, Kulshreshtha DK, Srimal RC, Dhawan BN. Hepatoprotective activity of Ricinus communis leaves. International journal of pharmacognosy. 1992 Jan 1; 30(4):241-50.

- [8] Sharma S, Sharma AD, Naseer M, Singh R. Formulation and evaluation of self-emulsifying drug delivery system of ibuprofen using castor oil. *Int J Pharm Pharm Sci*. 2011; 3:299-302.
- [9] Patel VR, Dumancas GG, Viswanath LC, Maples R, Subong BJ. Castor oil: properties, uses, and optimization of processing parameters in commercial production. *Lipid insights*. 2016 Jan; 9: LPI-S40233.
- [10] Becker T. Synthesis of Free Organotin (IV) Compounds Containing Nonsteroidal Anti-Inflammatory Drugs and their Immobilisation into Mesoporous Silica Nanoparticles. *MOA SIDE EFFECT TOXICITY*
- [11] Desu PK, Vaishnavi G, Divya K, Lakshmi U. An overview on preformulation studies. *Indo american journal of pharmaceutical sciences*. 2015 Oct 1; 2(10):1399-407.
- [12] Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, Hardwick HE, Docherty AB, Thwaites RS, Openshaw PJ, Baillie JK. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. *The Lancet Rheumatology*. 2021 Jul 1; 3(7):e498-506.
- [13] Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochemical pharmacology*. 2020 Oct 1; 180:114147.
- [14] Lau E. Preformulation studies. *Handbook of modern pharmaceutical analysis*. 2001 Jan 1; 3:173-224.
- [15] Alopaeus JF, Hagesæther E, Tho I. Micellisation mechanism and behaviour of Soluplus®-furosemide micelles: Preformulation studies of an oral nanocarrier-based system. *Pharmaceuticals*. 2019 Mar; 12(1):15.
- [16] Kumar D, Kumar A, Malik J. Preformulation studies of Drotaverine HCl: An integral part of formulation design. *Education*. 2016 Jul; 2020.
- [17] Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. *Aging and disease*. 2018 Feb;9(1):143.
- [18] McEvoy L, Carr DF, Pirmohamed M. Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity. *Frontiers in Pharmacology*. 2021; 12:1302.
- [19] Sostres C, Gargallo CJ, Lanás A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. *Arthritis research & therapy*. 2013 Jul; 15(3):1-8.
- [20] Jin X, Ramani C, Fulper L, Law T, Downey D, Kane A, Wynn D, inventors; Jin Xiao P, Fulper Lester D, Law Tak KU, Downey Dawn D, assignee. Ibuprofen-containing liquid filled hard capsules. United States patent application US 11/768, 229. 2008 Mar.
- [21] <https://draxe.com/nutrition/castor-oil/>
- [22] Amaral MH, Lobo JM, Ferreira DC. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. *AAPS PharmSciTech*. 2001 Jun; 2(2):14-21.
- [23] Wadher KJ, Rajendra K, Milind U. Sustained release metformin hydrochloride tablet using hydrogenated castor oil and stearic acid by melt granulation technique. *Der Pharmacia Lettre*. 2010;2(2):64-73.
- [24] Abdelkader H, Youssef Abdalla O, Salem H. Formulation of controlled-release baclofen matrix tablets II: influence of some hydrophobic excipients on the release rate and in vitro evaluation. *Aaps Pharmscitech*. 2008 Jun;9(2):675-83.
- [25] Singh P, Kumar P, Prasad N. Formulation and evaluation of aspirin tablets by using different lubricants in combination for better kinetic drug release study by PCP. *Evaluation*. 2017 Sep 30;28:0-28.
- [26] Amaral MH, Lobo JM, Ferreira DC. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. *AAPS PharmSciTech*. 2001 Jun;2(2):14-21.
- [27] Desu PK, Vaishnavi G, Divya K, Lakshmi U. *Pharmaceutical sciences*. *J. Pharm. Sci*. 2015;2(10).
- [28] Tripathi KD. *Farmacología en odontología: fundamentos*. Ed. Médica Panamericana; 2008 Jun 30.
- [29] Shin D, Lee SJ, Ha YM, Choi YS, Kim JW, Park SR, Park MK. Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. *Drug Design, Development and Therapy*. 2017;11:135.

- [30] Shah BM, Panda S, Reddy CU. Formulation and evaluation of sustained release matrix tablets of verapamil hydrochloride by melt granulation. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2012;4(3):501-6.
- [31] KAR A, AHMED AB. Enhancement of solubility and dissolution of ibuprofen by solid dispersion technique and formulation of sustained release tablets containing the optimised batch of solid dispersion. *International Journal of Current Pharmaceutical Research*. 2017 Sep 21:37-44.
- [32] Swain RP, Kumari TR, Panda SA. Formulation development and evaluation of sustained release ibuprofen tablets with acrylic polymers (Eudragit) and HPMC. *Int J Pharm Pharm Sci*. 2016;8(2):131-5.
- [33] Jan SU, Khan GM, Hussain I. Formulation development and investigation of ibuprofen controlled release tablets with hydrophilic polymers and the effect of co-excipients on drug release patterns. *Pak. J. Pharm. Sci*. 2012 Oct 1;25(4):751-6.
- [34] Chowdary KR, Hymavathi R. Formulation and dissolution rate studies on dispersible tablets of ibuprofen. *Indian journal of pharmaceutical sciences*. 2000;62(3):213.
- [35] Lewis A, editor. *Nonsteroidal anti-inflammatory drugs: Mechanisms and clinical uses*. Informa Health Care; 1993 Dec 14.
- [36] Astbury C. *Non-steroidal anti-inflammatory drugs. Mechanisms and clinical uses*. *Annals of the Rheumatic Diseases*. 1994 Nov;53(11):719.
- [37] Bond M. Pain education issues in developing countries and responses to them by the International Association for the Study of Pain. *Pain Research and Management*. 2011 Nov 1;16(6):404-6.
- [38] Prehn J, Ezzy D. Decolonising the health and well-being of Aboriginal men in Australia. *Journal of sociology*. 2020 Jun;56(2):151-66.
- [39] Jannat E, Al Arif A, Hasan MM, Zarziz AB, Rashid HA. Granulation techniques & its updated modules. *The Pharma Innovation*. 2016 Oct 1;5(10, Part B):134.
- [40] Ubhe TS, Gedam P. A Brief Overview on Tablet and It's Types. *Journal of Advancement in Pharmacology*. 2020;1(1).
- [41] Patel VR, Dumancas GG, Viswanath LC, Maples R, Subong BJ. Castor oil: properties, uses, and optimization of processing parameters in commercial production. *Lipid insights*. 2016 Jan;9:LPI-S40233.
- [42] Khoshayand MR, Abdollahi H, Shariatpanahi M, Saadatfard A, Mohammadi A. Simultaneous spectrophotometric determination of paracetamol, ibuprofen and caffeine in pharmaceuticals by chemometric methods. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2008 Aug 1;70(3):491-9.
- [43] Garrigues S, Galignani M, de la Guardia M. FIA—FT—IR determination of ibuprofen in pharmaceuticals. *Talanta*. 1993 Jan 1;40(1):89-93.
- [44] Amaral MH, Lobo JM, Ferreira DC. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. *AAPS PharmSciTech*. 2001 Jun;2(2):14-21.
- [45] Syed U, Khan GM, Muhammad S, Haroon KH, Khan KA, Kifayat U. Formulation, evaluation and effect of 3 new polymers and co-excipients on in-vitro controlled release patterns of flurbiprofen matrix tablets. *Lat. Am. J. Pharm*. 2013;32(9):1335-41.
- [46] Wadke DA, Serajuddin AT, Jacobson H. *Preformulation testing. Pharmaceutical dosage forms: Tablets*. 1989 Jun 5;1:1-73.
- [47] Bharate SS, Vishwakarma RA. Impact of preformulation on drug development. *Expert opinion on drug delivery*. 2013 Sep 1;10(9):1239-57.
- [48] Peck GE, Baley GJ, McCurdy VE, Banker GS. *Tablet formulation and design. Pharmaceutical dosage forms*. Marcel Dekker, New York. 1989 Jun 5:75-130.
- [49] Augsburger LL, Zellhofer MJ. *Tablet formulation*. In *Encyclopedia of Pharmaceutical Science and Technology*, Fourth Edition 2013 Jul 1 (pp. 3511-3521). CRC Press.
- [50] Waycott J, Pedell S, Vetere F, Ozanne E, Kulik L, Gruner A, Downs J. Actively engaging older adults in the development and evaluation of tablet technology. In *Proceedings of the 24th Australian Computer-Human Interaction Conference 2012* Nov 26 (pp. 643-652).
- [51] Bodduluri L, Boon MY, Dain SJ. Evaluation of tablet computers for visual function assessment. *Behavior Research Methods*. 2017 Apr;49(2):548-58.

- [52] Vidhya S, Narayanan BL, Malairajan P, Sahayaraja RJ, Kumar EP, Mahibalan S, Karpakavalli M, Balakumar C. Analytical method development and Validation for the Quantitative estimation of Cefditoren Pivoxil in tablet formulation by RP-HPLC. International Journal of Drug Development and Research. 2012;4(1):0-.
- [53] Patel BN, Suhagia BN, Patel CN. RP-HPLC method development and validation for estimation of darunavir ethanolate in tablet dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2012;4(3):270-3.
- [54] Sharma N, Rajput P, Thakkar A, Sarma GS. RP-HPLC method development for estimation of sildenafil citrate in tablets and in seminal fluid. Journal of Applied Pharmaceutical Science. 2012 Jun 1;2(6):172.

